Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 8/20 | 0.45 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398526 | 1.00 | PDK2 (0.45) | PDK2AKR1A1AKR1B1CYP11B2CYP11B1 | |
| SCHEMBL30322811 | 0.85 | MAOA (0.47) | PDK2CYP11B2KDM4ESMN1; SMN2MAOA | |
| SCHEMBL19009209 | 0.85 | MAOA (0.47) | PDK2CYP11B2KDM4ESMN1; SMN2MAOA | |
| SCHEMBL19147675 | 0.85 | PDK2 (0.58) | PDK2AKR1A1AKR1B1KDM4ESMN1; SMN2 | |
| SCHEMBL19009212 | 0.85 | MAOA (0.47) | PDK2CYP11B2KDM4ESMN1; SMN2MAOA | |
| SCHEMBL17816711 | 0.83 | PDK2 (0.56) | PDK2AKR1A1AKR1B1KDM4ESMN1; SMN2 | |
| SCHEMBL31617854 | 0.82 | PDK2 (0.43) | PDK2AKR1A1AKR1B1CYP11B2CYP11B1 | |
| SCHEMBL20687315 | 0.80 | PDK2 (0.57) | PDK2AKR1A1AKR1B1KDM4ESMN1; SMN2 | |
| SCHEMBL20323359 | 0.80 | CYP11B2 (0.41) | PDK2AKR1A1AKR1B1CYP11B2CYP11B1 | |
| SCHEMBL22609095 | 0.79 | PDK2 (0.45) | PDK2AKR1A1AKR1B1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220231234-A1 | Compounds comprising a hetero-fluorene group | NOVALED GMBH (DE) | 2022-07-21 | — | — | US | disclosed |
| CN-113853370-A | Compounds containing heterofluorene groups | 诺瓦尔德股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| WO-2020221570-A1 | COMPOUNDS COMPRISING A HETERO-FLUORENE GROUP | NOVALED GMBH (DE) | 2020-11-05 | — | — | WO | disclosed |
| EP-3733649-A1 | HETERO-FLUORENE DERIVATIVES AND THEIR USE IN ELECTRONIC DEVICES | Novaled GmbH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733649-A1 | HETERO-FLUORENE DERIVATIVES AND THEIR USE IN ELECTRONIC DEVICES | Novaled GmbH (DE) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220231234-A1 | Compounds comprising a hetero-fluorene group | AFF2, AFF1, AFF4 | PDK2 3893/4885AKR1A1 3960/4885AKR1B1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.